RE:RE:RE:RE:RE:AbbVie to Record $4 Billion Impairment on Stemcentrx AssetsBut testing on animals and testing on humans often has different results.
None the less, I hope that the next phase of trials will show that TLT has the golden egg for NMIBC and Glioblastoma Multiforme.
The stock is cheap enough now that the average joe could buy 10,000 shares and not lose too much if clinical trials went poorly. BUT if the trials go well, then there will be significant appreciation in the share price.
I am certain that many on here have seen bio stocks with great promise in Ph1 trials and then fizzle out in Ph2 or 3. I am hoping differently for TLT. But it is way too early to declare TLT a success after successful animal studies and just 6 patients.
AvvVie is a good example. They paid $ 5.8 billion for something they saw great potential in but has given very poor results.
I remain hopeful for TLT success going forward. GLTA.